Treatment of thrombotic cardiovascular diseases in people with haemophilia: A Japanese consensus study

Abstract

IntroductionCardiovascular diseases (CVD) that require long‐term anticoagulant and antiplatelet therapy presents a problem in people with haemophilia (PWH) who receive factor replacement therapy to reduce bleeding risk. Currently, there are no Japanese guidelines for the management of PWH with CVD.AimTo develop expert guidance on managing CVD in PWH in Japan.MethodsA steering committee of four experts (two haemophilia specialists, one thrombosis specialist, one cardiologist) identified 44 statements related to five key themes. An online questionnaire was produced comprising a mix of 4‐point Likert scale and multiple‐choice questions that was sent to specialists in the management of PWH with CVD in Japan. Consensus was defined as high or very high if a respective ≥75% or ≥90% of respondents agreed with a statement.ResultsOf 16 potential respondents, responses were received from 15 specialists. Of the Likert scale questions, 71% (29/41) achieved ≥90% agreement (very strong agreement), 17% (7/41) achieved 75%–89% agreement (strong agreement) and 15% (6/41) did not achieve consensus agreement. The three multiple‐choice questions failed to identify a strong preference. Agreement on specific target trough clotting factor levels for managing certain clinical situations, such as when in the presence of non‐valvular atrial fibrillation or myocardial infarction, was also achieved.ConclusionThe results of this consensus study provide a framework for cardiologists and haematologists to manage PWH who are at risk of, or who have, CVD. Implementation of the recommendations provided herein may improve outcomes for PWH with CVD.